Skip to main content
Fig. 7 | Cell Communication and Signaling

Fig. 7

From: Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability

Fig. 7

Compound D347-2761 interfered with c-Myc/Max heterodimerization. A Western blot analysis of c-Myc and Max expression in NCI-H929 cells treated by different dose of D347-2761 (2 μM, 5 μM and 10 μM). B HEK293T cells were transfected with 2 μg p3*Flag-CMV-9-c-Myc plasmids, then 10 μM D347-2761 was added into the medium for 48 h, IP assay analysis of c-Myc and Max expression. H IgG means heavy IgG and L IgG means light IgG. C GST pull down assay analysis of interaction between c-Myc and Max following different concentration of D347-2761 treatment. D HEK293T cells were transfected with c-Myc, c-Myc-luc and Renilla plasmids following different dose of D347-2761 treatment for 48 h, and luciferase reporter assay analysis of c-Myc promoter activity. E HEK293T cells were transfected with c-Myc, c-Myc-luc and Renilla plasmids following D347-2761 treatment for different time, and luciferase reporter assay analysis of c-Myc promoter activity. F. GST-c-Myc incubated with His-Max following different dose of D347-2761 treatment (100 μM, 150 μM and 200 μM), then biotin-labeled c-Myc response element probe was added into the reaction system for following EMSA assay

Back to article page